Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

HAART and response to therapy improve quality of life (QOL) of African patients with advanced HIV-associated Kaposi’s sarcoma (HIV-KS): a prospective analysis of QOL in the KAART trial

HAART and response to therapy improve quality of life (QOL) of African patients with advanced... Mosam et al. Infectious Agents and Cancer 2010, 5(Suppl 1):A30 http://www.infectagentscancer.com/content/5/S1/A30 MEETING ABSTRACTS Open Access HAART and response to therapy improve quality of life (QOL) of African patients with advanced HIV-associated Kaposi’s sarcoma (HIV-KS): a prospective analysis of QOL in the KAART trial 1* 1,2 2,3 1 4 5 1 1,6 Anisa Mosam , F Shaik , T Uldrick , T Esterhuizen , G Friedland , D Scadden , J Aboobaker , H Coovadia th From 12 International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI) Bethesda, MD, USA. 26-27 April, 2010 Background improving to 67 at month 12 (p<0.001). Significant Quality of Life (QOL) assessment is important in onco- improvements in median scores from baseline to month logy studies. Effect of therapy on QOL is important in 12 were seen in emotional, cognitive, and social scales, HIV-KS, as decreasing morbidity is a goal of therapy. but not physical function and role function. Most symp- This is the first prospective study to evaluate the effect of tom scales (fatigue, pain, dyspnea, insomnia, appetite, HAART, +/- chemotherapy, on QOL in African patients diarrhea, and constipation) showed significant improve- with HIV-KS. Within the KAART study, we assessed the ment over time. Improvement in nausea was borderline impact of HAART over 12 months in all patients, differ- (p=0.03). There were no statistically significant changes ences in QOL between arms, as well as associations over time between arms; however role function between QOL and several clinical parameters. (p=0.011) trended toward greater improvement in the CXT arm. Complete or partial response was associated Methods with increased global health scores (p<0.001), while KAART is a randomized, controlled, open label trial of number or severity of adverse events, adherence, HIV HAART vs. HAART plus chemotherapy (CXT) in treat- viral load, or CD4 count were not. ment-naive South African patients with HIV-KS. QOL outcomes were assessed prospectively in English or isiZulu Conclusion using EORTC-QOL30. We evaluated intra-group changes African HIV-KS patients benefit significantly in their between baseline and month 12 QOL scores (Wilcoxon overall global health status, functioning and symptoms rank sign test), changes between baseline and month 12 from HAART. Partial and complete responses to therapy QOL scores between the two groups (Mann-Whitney are significant predictors of global health, and the role of test), and the relationship between clinical responses and early chemotherapy in advanced HIV-KS merits further global QOL (Kruskal-Wallis test). Given multiple compari- investigation. Improving QOL is an important goal in the sons, p-values <0.01 are considered statistically significant; treatment of advanced KS in resource-limited settings. 0.01< p <0.05 represent important trends. QOL results from this study inform treatment paradigms for management of African patients with HIV-KS. Results 111 participants had QOL information. Median global Acknowledgements health score (perfect score = 100) was 50 at baseline, This article has been published as part of Infectious Agents and Cancer th Volume 5 Supplement 1, 2010: Proceedings of the 12 International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI). The full contents of the supplement are *Correspondence: mosama@ukzn.ac.za 1 available online at http://www.biomedcentral.com/1750-9378/5?issue=S1. University of KwaZulu Natal, Durban, South Africa Full list of author information is available at the end of the article © 2010 Mosam et al; licensee BioMed Central Ltd. Mosam et al. Infectious Agents and Cancer 2010, 5(Suppl 1):A30 Page 2 of 2 http://www.infectagentscancer.com/content/5/S1/A30 Author details 1 2 University of KwaZulu Natal, Durban, South Africa. CAPRISA and SA- 3 4 Columbia Fogarty AITRP. Columbia University, New York, NY, USA. Yale University School of Medicine, New Haven, CT, USA. Harvard Medical School, Boston, MA, USA. Reproductive Health and HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa. Published: 11 October 2010 doi:10.1186/1750-9378-5-S1-A30 Cite this article as: Mosam et al.: HAART and response to therapy improve quality of life (QOL) of African patients with advanced HIV- associated Kaposi’s sarcoma (HIV-KS): a prospective analysis of QOL in the KAART trial. Infectious Agents and Cancer 2010 5(Suppl 1):A30. Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color figure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution Submit your manuscript at www.biomedcentral.com/submit http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Infectious Agents and Cancer Springer Journals

HAART and response to therapy improve quality of life (QOL) of African patients with advanced HIV-associated Kaposi’s sarcoma (HIV-KS): a prospective analysis of QOL in the KAART trial

Download PDF
2 pages

Loading next page...
 
/lp/springer-journals/haart-and-response-to-therapy-improve-quality-of-life-qol-of-african-rmYm02cdKR

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © 2010 by Mosam et al; licensee BioMed Central Ltd.
Subject
Biomedicine; Cancer Research; Infectious Diseases; Oncology
eISSN
1750-9378
DOI
10.1186/1750-9378-5-S1-A30
Publisher site
See Article on Publisher Site

Abstract

Mosam et al. Infectious Agents and Cancer 2010, 5(Suppl 1):A30 http://www.infectagentscancer.com/content/5/S1/A30 MEETING ABSTRACTS Open Access HAART and response to therapy improve quality of life (QOL) of African patients with advanced HIV-associated Kaposi’s sarcoma (HIV-KS): a prospective analysis of QOL in the KAART trial 1* 1,2 2,3 1 4 5 1 1,6 Anisa Mosam , F Shaik , T Uldrick , T Esterhuizen , G Friedland , D Scadden , J Aboobaker , H Coovadia th From 12 International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI) Bethesda, MD, USA. 26-27 April, 2010 Background improving to 67 at month 12 (p<0.001). Significant Quality of Life (QOL) assessment is important in onco- improvements in median scores from baseline to month logy studies. Effect of therapy on QOL is important in 12 were seen in emotional, cognitive, and social scales, HIV-KS, as decreasing morbidity is a goal of therapy. but not physical function and role function. Most symp- This is the first prospective study to evaluate the effect of tom scales (fatigue, pain, dyspnea, insomnia, appetite, HAART, +/- chemotherapy, on QOL in African patients diarrhea, and constipation) showed significant improve- with HIV-KS. Within the KAART study, we assessed the ment over time. Improvement in nausea was borderline impact of HAART over 12 months in all patients, differ- (p=0.03). There were no statistically significant changes ences in QOL between arms, as well as associations over time between arms; however role function between QOL and several clinical parameters. (p=0.011) trended toward greater improvement in the CXT arm. Complete or partial response was associated Methods with increased global health scores (p<0.001), while KAART is a randomized, controlled, open label trial of number or severity of adverse events, adherence, HIV HAART vs. HAART plus chemotherapy (CXT) in treat- viral load, or CD4 count were not. ment-naive South African patients with HIV-KS. QOL outcomes were assessed prospectively in English or isiZulu Conclusion using EORTC-QOL30. We evaluated intra-group changes African HIV-KS patients benefit significantly in their between baseline and month 12 QOL scores (Wilcoxon overall global health status, functioning and symptoms rank sign test), changes between baseline and month 12 from HAART. Partial and complete responses to therapy QOL scores between the two groups (Mann-Whitney are significant predictors of global health, and the role of test), and the relationship between clinical responses and early chemotherapy in advanced HIV-KS merits further global QOL (Kruskal-Wallis test). Given multiple compari- investigation. Improving QOL is an important goal in the sons, p-values <0.01 are considered statistically significant; treatment of advanced KS in resource-limited settings. 0.01< p <0.05 represent important trends. QOL results from this study inform treatment paradigms for management of African patients with HIV-KS. Results 111 participants had QOL information. Median global Acknowledgements health score (perfect score = 100) was 50 at baseline, This article has been published as part of Infectious Agents and Cancer th Volume 5 Supplement 1, 2010: Proceedings of the 12 International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI). The full contents of the supplement are *Correspondence: mosama@ukzn.ac.za 1 available online at http://www.biomedcentral.com/1750-9378/5?issue=S1. University of KwaZulu Natal, Durban, South Africa Full list of author information is available at the end of the article © 2010 Mosam et al; licensee BioMed Central Ltd. Mosam et al. Infectious Agents and Cancer 2010, 5(Suppl 1):A30 Page 2 of 2 http://www.infectagentscancer.com/content/5/S1/A30 Author details 1 2 University of KwaZulu Natal, Durban, South Africa. CAPRISA and SA- 3 4 Columbia Fogarty AITRP. Columbia University, New York, NY, USA. Yale University School of Medicine, New Haven, CT, USA. Harvard Medical School, Boston, MA, USA. Reproductive Health and HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa. Published: 11 October 2010 doi:10.1186/1750-9378-5-S1-A30 Cite this article as: Mosam et al.: HAART and response to therapy improve quality of life (QOL) of African patients with advanced HIV- associated Kaposi’s sarcoma (HIV-KS): a prospective analysis of QOL in the KAART trial. Infectious Agents and Cancer 2010 5(Suppl 1):A30. Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color figure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution Submit your manuscript at www.biomedcentral.com/submit

Journal

Infectious Agents and Cancer – Springer Journals

Published: Oct 11, 2010

There are no references for this article.